Medtronic’s Amplify Spine Product Not Approvable, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
Medtronic received a non-approvable letter from FDA for its Amplify rhBMP-2 Matrix spinal treatment, the company disclosed in a March 9 regulatory filing.